AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did Mineralys Shares Plunge 11.33%? Goldman Sachs Cuts Target
Generated by AI AgentAinvest Movers Radar
Thursday, May 1, 2025 5:42 am ET1min read
On May 1, 2025,
shares plummeted by 11.33% in pre-market trading, marking a significant downturn for the company.Goldman Sachs recently adjusted its price target for
, reducing it from $28.00 to $24.00 while maintaining a "buy" rating. This revision reflects the firm's updated outlook on the company's prospects, which may have contributed to the recent decline in share price.Additionally, Boothbay Fund Management LLC acquired 44,067 shares of Mineralys Therapeutics, indicating continued interest from institutional investors despite the recent price drop. This acquisition suggests that some investors remain optimistic about the company's long-term potential.
Mineralys Therapeutics has experienced a range of share prices over the past year, with a fifty-two week low of $8.24 and a fifty-two week high of $18.38. This volatility underscores the challenges and opportunities facing the company as it navigates the competitive landscape of the biotechnology sector.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Two Harbors (TWO) Surges 1.59% to Monthly High Amid Anticipation of $1.3B UWM Acquisition
Dec.19 2025
Trane Technologies Surges 1.46% on Q3 Earnings, Analysts Target $550
Dec.19 2025
Rivian (RIVN) Surges 27.34% on Analyst Upgrades, Q3 Revenue Growth Drives Rebound
Dec.19 2025
Tata Chemicals Share Price Soars 119.32% on Novabay Acquisition Drive
Dec.19 2025
X3 Holdings (XTKG) Rallies 36.76% Intraday, 22.50% in Three Sessions on Technical Rebound and Speculative Buying
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet